TAMEing ADPKD with metformin: safe and effective?
- 1 September 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International
- Vol. 100 (3), 513-515
- https://doi.org/10.1016/j.kint.2021.07.021
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)Kidney International, 2021
- Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney diseaseEBioMedicine, 2019
- The combination of metformin and 2‐deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney diseaseBritish Journal of Pharmacology, 2018
- Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivoNature Medicine, 2018
- Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 DeficiencyScientific Reports, 2017
- Metformin Action: Concentrations MatterCell Metabolism, 2015
- Low Concentrations of Metformin Suppress Glucose Production in Hepatocytes through AMP-activated Protein Kinase (AMPK)*Online Journal of Public Health Informatics, 2014
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesisProceedings of the National Academy of Sciences of the United States of America, 2011